← Leaderboards
Margaret Victoria Ragni
University Of Pittsburgh At Pittsburgh
$7,547,687
Attributed
$7,547,687
Total exposure
11
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $750.8K · FY2005–21$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$7,547,687 · 11
By mechanism
U01$2,784,949 · 1
R01$2,292,983 · 2
U34$1,357,802 · 2
R34$770,862 · 1
T35$328,524 · 1
M01$12,567 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- David C Whitcomb$21,073,858
- John S Lazo$20,744,955
- Simon C Watkins$30,927,669
- David M Krisky$2,047,518
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchPhysiciansMemberResearch DesignReview LiteratureResearch Project GrantsUniversitiesTrainingFutureEpidemiologyDesignOralCoagulation ProcessLearningHematologyFundamental ResearchInterestRadiation OncologyBiomedical ResearchMentorsDisciplineData CollectionCareerOncology
Grant awards (40)
Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial$675,147
U01 · FY2021 · HL · contact PI
Training Students in Biomedical Research in Hematology$17,192
T35 · FY2021 · HL · contact PI
Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial$702,245
U01 · FY2020 · HL · contact PI
Training Students in Biomedical Research in Hematology$26,568
T35 · FY2020 · HL · contact PI
Training Students in Biomedical Research in Hematology$26,114
T35 · FY2019 · HL · contact PI
Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial$702,344
U01 · FY2018 · HL · contact PI
Training Students in Biomedical Research in Hematology$25,672
T35 · FY2018 · HL · contact PI
Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial$705,213
U01 · FY2017 · HL · contact PI
Training Students in Biomedical Research in Hematology$25,240
T35 · FY2017 · HL · contact PI
Feasibility of the Von Willebrand Disease Minimize Trial$213,921
U34 · FY2015 · HL · contact PI
Training Students in Biomedical Research in Hematology$15,156
T35 · FY2015 · HL · contact PI
Feasibility of the Von Willebrand Disease Minimize Trial$213,017
U34 · FY2014 · HL · contact PI
Training Students in Biomedical Research in Hematology$24,008
T35 · FY2014 · HL · contact PI
Feasibility of the Hemophilia INHIBIT Trial$338,817
U34 · FY2013 · HL · contact PI
Feasibility of the Von Willebrand Disease Minimize Trial$215,533
U34 · FY2013 · HL · contact PI
Training Students in Biomedical Research in Hematology$23,609
T35 · FY2013 · HL · contact PI
Feasibility of the Hemophilia INHIBIT Trial$376,514
U34 · FY2012 · HL · contact PI
Hemophilia Adult Prophylaxis Study$350,670
R34 · FY2012 · HL · contact PI
Training Students in Biomedical Research in Hematology$23,609
T35 · FY2012 · HL · contact PI
Hemophilia Adult Prophylaxis Study$420,192
R34 · FY2011 · HL · contact PI
Training Students in Biomedical Research in Hematology$21,238
T35 · FY2011 · HL · contact PI
Training Students in Biomedical Research in Hematology$17,410
T35 · FY2009 · HL · contact PI
Training Students in Biomedical Research in Hematology$20,677
T35 · FY2008 · HL · contact PI
Training Students in Biomedical Research in Hematology$20,677
T35 · FY2007 · HL · contact PI
Training Students in Biomedical Research in Hematology$20,677
T35 · FY2006 · HL · contact PI
Training Students in Biomedical Research in Hematology$20,677
T35 · FY2005 · HL
PH2 COMP HEMOSTATIC OF ESCAL DOSES INTERLEUKIN-11 W/TYPE 1 VON WILLEBRAND DIS$6,995
M01 · FY2005 · RR
IMPACT OF HIV ON HEPATITIS C IN HEMOPHILIA (3HS)$2,266
M01 · FY2005 · RR
Impact of HIV on Hepatitis C Infection in Hemophilia$207,197
R01 · FY2004 · HL
PH1 SFY STY PTS W/SEVERE HEMOPHILIA B USING AAVV$2,289
M01 · FY2004 · RR
IMPACT OF HIV ON HEPATITIS C IN HEMOPHILIA (3HS)$1,017
M01 · FY2004 · RR
Impact of HIV on Hepatitis C Infection in Hemophilia$519,255
R01 · FY2003 · HL
Impact of HIV on Hepatitis C Infection in Hemophilia$515,165
R01 · FY2002 · HL
FACTOR VIII VECTOR FOR SEVERE HEMOPHILIA A$0
M01 · FY2002 · RR
FACTOR VIII VECTOR FOR SEVERE HEMOPHILIA A$0
M01 · FY2002 · RR
Impact of HIV on Hepatitis C Infection in Hemophilia$526,696
R01 · FY2001 · HL
EPIDEMIOLOGY AND IMMUNOLOGY OF HEMOPHILIA A INHIBITORS$262,335
R01 · FY2001 · HL
FACTOR VIII VECTOR FOR SEVERE HEMOPHILIA A$0
M01 · FY2001 · RR
EPIDEMIOLOGY AND IMMUNOLOGY OF HEMOPHILIA A INHIBITORS$262,335
R01 · FY2000 · HL
FACTOR VIII VECTOR FOR SEVERE HEMOPHILIA A$0
M01 · FY2000 · RR